欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (3): 271-274.

• 基础研究 • 上一篇    下一篇

β3肾上腺素能受体激动剂对离体人肺脏肺泡液体清除的作用

李乃静1, 李伟2, 谷秀3, 李岩1, 何平1   

  1. 1中国医科大学附属盛京医院老年病科,沈阳 110004,辽宁;
    2沈阳药科大学药物分析教研室,沈阳 110004,辽宁;
    3中国医科大学附属盛京医院呼吸内科,沈阳 110004,辽宁
  • 收稿日期:2013-03-11 修回日期:2014-03-07 出版日期:2014-03-26 发布日期:2014-04-10
  • 作者简介:李乃静,女,博士,副教授,主要从事老年呼吸系统疾病的研究。Tel: 18940257247 E-mail: lnjlw2003@163.com
  • 基金资助:
    辽宁省科学技术计划项目(201202245);教育部留学回国人员科研启动基金(教外司留[2011]1139)

Effect of CGP-12177 on alveolar fluid clearance in isolated human lung

LI Nai-jing1, LI Wei2, GU Xiu3, LI Yan1, HE Ping1   

  1. 1Department of Gerontology, the Shengjing Affiliated Hospital, China Medical University, Shenyang 110004, Liaoning, China;
    2College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110004, Liaoning, China;
    3Department of Respiratory Medicine, the Shengjing Affiliated Hospital, China Medical University, Shenyang 110004, Liaoning, China
  • Received:2013-03-11 Revised:2014-03-07 Online:2014-03-26 Published:2014-04-10

摘要: 目的: 制备离体人肺脏模型,探讨β3肾上腺素能受体激动剂CGP-12177对肺泡液体清除率(AFC)的作用及其机制。方法: 以肺泡内Evans蓝标记的白蛋白浓度的变化测定AFC。首先将 10-4 mol/L 到 10-7 mol/L 的CGP-12177分别灌注到离体人肺脏肺泡腔内,测定AFC的变化。然后将 10-5 mol/L CGP-12177分别与α受体阻滞剂酚妥拉明、β1受体阻滞剂阿替洛尔、β2受体阻滞剂ICI-118551、β3受体阻滞剂SR59230A、钠通道阻断剂氨氯吡咪、Na+-K+-ATP酶阻断剂哇巴因混合后灌注到离体人肺脏肺泡腔内,测定AFC的变化。结果: 10-7 mol/L 和 10-4 mol/L CGP-12177对离体人肺脏肺泡液体清除率没有影响,10-6 mol/L 和10-5 mol/L 的CGP-12177能够显著提高离体人肺脏肺泡液体清除率。CGP-12177增加离体人肺脏AFC的作用能够被SR59230A、氨氯吡咪和哇巴因抑制。结论: 高选择性CGP-12177主要通过调节Na+-K+-ATP酶的活性提高离体人肺脏肺泡液体清除能力。

关键词: 离体人肺脏, 肾上腺素能受体激动剂, 肺水肿

Abstract: AIM: To establish the model of isolated human lung, and to study the effect of CGP-12177 on alveolar fluid clearance (AFC) in isolated human lung and the mechanisms involved.METHODS: The AFC was measured by the concentration of Evansblue-labeled album in the istilled and aspirated solution. Isomolar albumin solution in the presence of 10-4 mol/L to 10-7 mol/L CGP-12177 (selective β3-adrenergic agonists) was injected into the alveolar spaces in isolated human lung, and AFC was measured. 10-5 mol/L CGP-12177 combined with phentolamine (α receptor antagonist), atenolol (β1 receptor antagonist), ICI-118551 (β2 receptor antagonist), SR59230A (β3 receptor antagonist), sodium channel blockers or Na+/K+-ATPase blockers were perfused into the alveolar space of isolated human lung.RESULTS: 10-5 mol/L and 10-6 mol/L CGP-12177 increased AFC significantly in isolated human lung,but 10-4 mol/L and 10-7 mol/L CGP-12177 didn't increase AFC. The AFC-stimulating effect of CGP-12177 was decreased by SR59230A, amiloride and ouabain.CONCLUSION: CGP-12177, a β3-adrenergic agonist, can increase AFC in isolated human lung by promoting the transport of Na+-K+-ATPase.

Key words: isolated human lung, adrenergic agonist, lung injury

中图分类号: